POWDERMED LAUNCHES PRECLINICAL AVIAN FLU VACCINE TRIAL
PowderMed, an immunotherapeutics, has announced that it has progressed its H5N1
avian influenza vaccine program into the final stages of preclinical development.
PowderMed has produced an H5N1 vaccine by cloning the H5 gene from the current
circulating avian flu strain into the company's proprietary DNA vaccine backbone
and the vaccine is now ready for development. Manufacturing and toxicology studies
are now in progress, and it is anticipated that this vaccine will enter clinical
trials by the middle of 2006.
PowderMed has carried out a detailed feasibility study with contract manufacturing
partners, which concludes that it could establish a manufacturing capability
with a surge capacity of 150 million influenza vaccine doses in a three-month
period. The avian flu vaccine uses the same standard DNA vaccine backbone as
PowderMed's annual flu vaccine, which has already successfully completed a Phase
I clinical trial and will enter Phase IIb trials in 2006.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May